



1/2  
SEQUENCE LISTING

<110> DUBOIS, Claire

5 <120> USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT  
OF INFLAMMATORY OR MATRIX REMODELLING DISEASES

<130> 85761-28

10 <140> US 09/885,914  
<141> 2001-06-22

<150> US 60/213,995  
<151> 2000-06-26

15 <150> CA 2,312,109  
<151> 2000-06-23

<160> 3

20 <170> PatentIn version 3.2

<210> 1  
<211> 4

25 <212> PRT  
<213> Homo sapiens

<220>  
30 <221> SITE  
<222> (1)..(4)  
<223> Reactive site of alphas-antitrypsin

<400> 1

35 Ala Ile Pro Met  
1

40 <210> 2  
<211> 4  
<212> PRT  
<213> Artificial Sequence

45 <220>  
<223> Variant of Homo sapiens alphas-antitrypsin reactive site

<220>  
50 <221> MUTAGEN  
<222> (1)..(1)  
<223> Ala355 to Arg355 variant of reactive site of alphas-antitrypsin

<220>  
55 <221> MUTAGEN  
<222> (4)..(4)  
<223> Met358 to Arg358 variant of reactive site of alphas-antitrypsin

&lt;400&gt; 2

Arg Ile Pro Arg

1

&lt;210&gt; 3

&lt;211&gt; 4

&lt;212&gt; PRT

10 &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide

15

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)..(1)

20 &lt;223&gt; Arg at position 1 is modified at its amino group with a decanoyl group

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (4)..(4)

25 <223> Arg at position 4 is modified at its carboxyl group with a -CH<sub>2</sub>Cl group

&lt;400&gt; 3

30 Arg Val Lys Arg

1